AI Transparency Report
The Pharmaceutical Security Institute Inc (PSI) demonstrates consistent financial activity, with revenues generally exceeding expenses over the past decade, contributing to a healthy asset base of over $3 million as of 2023. The organization's spending efficiency appears strong, particularly given its mission in pharmaceutical security, which often involves specialized expertise and international collaboration. For instance, in 2022, PSI reported revenues of $2,254,106 against expenses of $1,854,717, indicating a surplus that can be reinvested into its programs or reserves. The absence of reported officer compensation across all available filings suggests a high degree of financial transparency and a commitment to directing resources towards its mission rather than executive salaries. This practice is a significant positive indicator for donors and stakeholders, reflecting a lean operational model.
However, the latest filing for 2023 shows expenses ($2,297,620) slightly exceeding revenues ($2,203,877), resulting in a minor deficit for that year. While not a significant concern in isolation, it warrants monitoring to ensure it doesn't become a trend. The organization's assets have remained robust, fluctuating but generally increasing over time, from $1,628,507 in 2014 to $3,048,080 in 2023, providing a solid financial cushion. The consistent reporting of zero officer compensation is a hallmark of strong transparency and a focus on mission-driven spending, which is commendable for a nonprofit of this size and scope.